TrialLeukemia2017

A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

S Verstovsek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.